TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-08 5:00 PM EST | TempraMed Technologies Ltd
CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients - - Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than previously published real-world data for pom-refractory, bispecific or anti-B
2025-12-07 8:00 AM EST | CellCentric, Inc
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-05 5:00 PM EST | TempraMed Technologies Ltd
Restart Life Sciences Announces Closing First Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement"). Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a p
Technology, Biotechnology, Health
2025-12-05 5:00 PM EST | Restart Life Sciences Corp.
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
New York, New York--(Newsfile Corp. - December 5, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("
2025-12-05 8:01 AM EST | OS Therapies
Stoked Bio Licenses Global Rights for Novel Antibiotic from McMaster University
Hamilton, Ontario--(Newsfile Corp. - December 4, 2025) - Stoked Bio Inc., a Canadian biotechnology company focused on the development of novel anti-infectives and cancer therapeutics, announced today it has secured an exclusive, glo
2025-12-04 9:12 AM EST | StokedBio
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee: On-boarding of all new patients entering Hemostemix treatment programs;
Biotechnology, Pharmaceuticals, Health
2025-12-04 9:10 AM EST | Hemostemix Inc.
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M. ET featuring a conversation between CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim™ cochlear implant. Event: Envoy Medical Fireside Chat
Biotechnology, Healthcare and Hospitals
2025-12-04 8:00 AM EST | Envoy Medical, Inc.
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprie
Biotechnology, Pharmaceuticals, Health
2025-12-04 7:00 AM EST | PreveCeutical Medical Inc.
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey. Defence
Biotechnology, Pharmaceuticals, Health
2025-12-04 3:15 AM EST | Defence Therapeutics Inc.
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements. Hemostemix will highlig
Biotechnology, Pharmaceuticals, Health
2025-12-03 2:05 PM EST | Hemostemix Inc.
Microbiome Labs Launches DigestMate, a 2-in-1 Digestive Enzyme and Probiotic Formula
Franklinton, North Carolina--(Newsfile Corp. - December 3, 2025) - Microbiome Labs, a leader in microbiome-based solutions, today announced the launch of DigestMate™, a 2-in-1 digestive enzyme and probiotic formula. Digestive health challenges are on the rise in America, impacting millions of lives and driving demand for innovative solutions. According to recent data from the Centers for Disease Control and Prevention (CDC) and the National Institute of Diabetes and Digestive and
2025-12-03 11:44 AM EST | Microbiome Labs
BioHarvest Sciences Announces Launch of VINIA Blood Flow Hydration Product
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow
Biotechnology, Pharmaceuticals, Health
2025-12-03 7:30 AM EST | BioHarvest Sciences Inc.
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance One of many distribution agreements in pipeline for Europe as part of TempraMed's def
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-02 5:00 PM EST | TempraMed Technologies Ltd
BYT Announces Normal Course Issuer Bid and Results of Its Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") announces that it intends to initiate a normal course issuer bid ("NCIB") through the facilities of the Canadian Securities Exchange ("CSE") or alternative trading systems and the results from its most recent annual general meeting of shareholders held on October 16, 2025. Normal Course Issuer Bid The Board of the Company belie
Technology, Biotechnology, Construction / Building, Machinery
2025-12-02 4:54 PM EST | BYT Holdings Ltd.
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company. At closing,
Biotechnology, Pharmaceuticals
2025-12-02 9:53 AM EST | PharmaTher Holdings Ltd.
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeo
Biotechnology, Pharmaceuticals, Health
2025-12-02 9:10 AM EST | Hemostemix Inc.
Envoy Medical Announces the Grant of Its 40th U.S. Patent
White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents. U.S. Paten
Biotechnology, Healthcare and Hospitals
2025-12-02 8:00 AM EST | Envoy Medical, Inc.
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ
Technology, Biotechnology, Healthcare and Hospitals
2025-12-01 8:30 AM EST | BioMark Diagnostics, Inc.
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis. Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression. The ARCHER data strengthen
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-12-01 7:27 AM EST | Cardiol Therapeutics Inc.